Amylin took a 26% hit today on the FDA rejecting its equivalence study of exenatide LAR made at Alkermes and at Amylin’s facilities. This probably takes away first-mover advantage on a long-acting exenatide from AMLN (when compared with liraglutide from Novo) and increases the likelihood of another commercial failure with exenatide LAR (along with Byetta)
Filed under: Uncategorized
